This review summarizes the current knowledge and potential use of immune-modulating drugs and hypomethylating agents in preventing or treating relapse after allogeneic HCT. The authors discuss the anti-tumor properties of these agents as well as their immunomodulatory qualities, and explain how they are being used alone or in combination with adoptive immunotherapy after allogeneic HCT to enhance graft-versus-tumor effects.
Immune-Modulating Drugs, Hypomethylating Agents to Treat Relapse
Oct 2013